2024
Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis
Odanović N, Schwann A, Zhang Z, Kapadia S, Kunnirickal S, Parise H, Tirziu D, Ilic I, Lansky A, Pietras C, Shah S. Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis. Open Heart 2024, 11: e002852. PMID: 39353703, PMCID: PMC11448144, DOI: 10.1136/openhrt-2024-002852.Peer-Reviewed Original ResearchConceptsCoronary Vasomotor Disorders International Study GroupRate of MACEReduced coronary flow reserveCoronary flow reservePrognosis of patientsVasospastic anginaPatient yearsMyocardial infarctionPrimary outcomeIncidence of primary outcomeLong-term prognosis of patientsSystematic reviewMeta-analysisLong-term prognosisInternational Study GroupAdverse cardiovascular eventsLong-term outcomesImaging stress testsMeta-analysis of studiesRandom-effects modelWeb of ScienceINOCACardiovascular eventsFollow-upVasomotor disordersDetermining the Cause of Coronary Vasomotor Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries: Design and Rationale of the DISCOVER INOCA Prospective, Multicenter Registry
Shah S, Tremmel J, Henry T, Smilowitz N, Prasad M, Kobayashi Y, Henry G, Samady H, Samuels B, Lerman A, Moses J, Pietras C, Zhang Z, Tirziu D, Parise H, Cristea E, Chamié D, Grubman D, Henrici K, Matmusaeva E, Latif N, Cigarroa N, Lansky A. Determining the Cause of Coronary Vasomotor Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries: Design and Rationale of the DISCOVER INOCA Prospective, Multicenter Registry. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102046. PMID: 39132594, PMCID: PMC11308755, DOI: 10.1016/j.jscai.2024.102046.Peer-Reviewed Original ResearchCoronary function testingObstructive coronary artery diseaseCoronary artery diseaseNonobstructive coronary arteriesLong-term outcomesFollow-upVasomotor disordersEnd pointsComposite of cardiovascular deathCoronary arteryLong-term follow-upCoronary microvascular dysfunctionDiagnostic coronary angiographyCardiovascular adverse eventsAdverse cardiovascular eventsCoronary vasomotor disordersOptical coherence tomographySymptomatic myocardial bridgingShort-term end pointsAtherosclerotic plaque burdenIschemic heart diseaseLong-term end pointsINOCA patientsAcetylcholine provocationPatient-reported outcome measures
2022
Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis.
Donatelle M, Agasthi P, Parise H, Igyarto Z, Martinsen B, Leon M, Beohar N. Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis. Journal Of Invasive Cardiology 2022, 34: e696-e700. PMID: 36200995, DOI: 10.25270/jic/22.00066.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisNon-AS cohortAortic stenosisNon-AS patientsSuccessful stent placementOrbital atherectomyStent placementOA useHospital major adverse cardiovascular eventsSevere calcific coronary artery diseaseCalcific coronary artery diseaseConcomitant severe aortic stenosisMajor adverse cardiovascular eventsCoronary orbital atherectomyIdeal revascularization strategyAdverse cardiovascular eventsMount Sinai Medical CenterProspective randomized trialsGlomerular filtration rateCoronary artery diseaseSinai Medical CenterPaucity of dataAngiographic complicationsMACE rateCardiovascular events
2012
Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Fiocca L, Guagliumi G, Rossini R, Parise H, Musumeci G, Sirbu V, Lortkipanidze N, Yu J, Mihalcsik L, Vassileva A, Valsecchi O, Gavazzi A, Mehran R, Stone G. Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. The American Journal Of Cardiology 2012, 111: 196-201. PMID: 23111141, DOI: 10.1016/j.amjcard.2012.09.019.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionAcute Myocardial Infarction trialKillip class IIIMyocardial Infarction trialOutcomes of patientsElevation myocardial infarctionHarmonizing OutcomesMyocardial infarctionMyocardial Infarction flow grade 3Major adverse cardiovascular eventsNet adverse clinical eventsClass IIIHORIZONS-AMI trialTrial eligible groupAdverse cardiovascular eventsHigh-risk featuresAdverse clinical eventsVentricular ejection fractionBroad inclusion criteriaFinal ThrombolysisMajor bleedingCardiovascular eventsCause mortalityAdverse eventsBaseline characteristics
2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarctionPredictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011, 7: 74-83. PMID: 21550906, DOI: 10.4244/eijv7i1a14.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsPaclitaxel-eluting stentsMyocardial infarctionIndependent predictorsID-TLRID-TVRCardiac deathCardiovascular eventsSPIRIT IIStent deploymentDrug-eluting stent deploymentPredictors of deathAdverse clinical outcomesCoronary artery diseaseSuperior clinical efficacyIschaemia-driven revascularisationNumber of lesionsArtery diseaseCoronary stentingClinical outcomesClinical efficacyAdverse outcomesPaclitaxel-eluting stent deploymentClinical trials